Recombinant CTLA-4 (Ipilimumab Biosimilar) antibody
Reactivity: Human
FACS, in vivo
Host: Mouse
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all CTLA-4 (Ipilimumab Biosimilar) products
- CTLA-4 (Ipilimumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This CTLA-4 (Ipilimumab Biosimilar) antibody is un-conjugated
- Application
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- Purpose
- Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody
- Specificity
- The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.
- Characteristics
- Recombinant fully human IgG1 monoclonal antibody.
- Purification
- Protein A affinity column
- Purity
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- Sterility
- 0.2 μm filtered
- Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method.
- Immunogen
- The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.
- Isotype
- IgG1 kappa
-
-
- Application Notes
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
- Preservative
- Without preservative
- Handling Advice
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- Expiry Date
- 12 months
-
- Target
- CTLA-4 (Ipilimumab Biosimilar)
- Abstract
- CTLA-4 (Ipilimumab Biosimilar) Products
- Synonyms
- CD antibody, CD152 antibody, CELIAC3 antibody, CTLA-4 antibody, GRD4 antibody, GSE antibody, IDDM12 antibody, cytotoxic T-lymphocyte associated protein 4 antibody, CTLA4 antibody
- Target Type
- Biosimilar
- Background
-
What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.
-
You are here:
